Invested in Sustainable Value Creation
Wavelength’s Operating Executives specialize
in the
nexus of Lifesciences, Healthcare, and Technology.
We focus on delivering sustainable value...
not on account development.
Expertise Bound With Long Term Perspective
Wavelength’s Operating Executives specialize in the nexus of Lifesciences, Healthcare, and Technology. We deliver transformations resulting in sustainable business value.
We solve complex problems with small teams possessing deep industry expertise. Rolling up our sleeves, we get our hands dirty and work quickly to distill and resolve your needs - driven by an energy and passion for great results. You can count on us to introduce fresh, sound ideas tempered by an experience-tested dose of realism. We always align with our business partners through shared interests.
Our approach will be most refreshing if you’ve ever been oversupplied with high dollar, marginal talent, sold work that didn’t move the needle on the business, or received a strategic plan filled with bright, but flawed and non-implementable ideas.
We’ve held many roles - executives, entrepreneurs, and consultants. These experiences mean we have seen numerous scenarios from multiple viewpoints. You will never have to question our loyalty. When you partner with us, it’s your agenda, period.
If all this resonates with you, then we are
Global News in Lifesciences, Healthcare, and Technology
New Wave Buys Paris Glove
New Wave Group, of Sweden, has acquired Paris Glove of Canada, according to a Dec. 1 statement. Financial terms weren't announced.
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
First Treatment to Demonstrate Superior Benefit in a Phase 3 Study Compared with Another Targeted Agent in Advanced RCC
NEW YORK--(Healthcare Sales & Marketing Network)-- Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has a...
Biopharmaceuticals, Oncology, FDA
Pfizer, INLYTA, axitinib, kinase inhibitor, renal cell carcinoma
UFC President Calls Out Anonymous, Plugs SOPA, Gets KTFO
Dana White may think twice before picking a fight with the world's largest hacker collective
NEA Backs Seed Fund For Students With Cambridge Focus
The Experiment Fund, a new seed stage investment fund, opened for business with backing from New Enterprise Associates. The fund is designed to support student start-ups and to nurture novel technologies created in Cambridge, Mass., or by those who started their educations there. Some angel investors are expected to participate. PRESS RELEASE Early Stage Venture Fund launches in Cambridge, Mass. New [...]
Saladax Biomedical, Inc. Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer
Kevin M. Harter, former Saladax Executive Chairman, Named Interim CEO
BETHLEHEM, Pa., Jan. 27, 2012 (HSMN NewsFeed) -- Saladax Biomedical, Inc., a privately-held company developing and commercializing novel diagnostic assays to achieve the promise of ...
Diagnostics, Personalized Medicine, Personnel
Saladax Biomedical, MyCare
HP Dumps Ex-Palm CEO, Celebrates Mobile-free Future
Computer maker says no to progress, drops another shovel of dirt on webOS's grave